Capricor Therapeutics Inc

Capricor trades with a striking 20.82% short float, nearly double typical pharmaceutical levels, suggesting meaningful skepticism from institutional traders despite the $1.7B market cap. The stock's RSI of 47.6 sits in neutral territory—neither overbought nor oversold—while sitting below its 52-week high, indicating downward momentum from recent peaks. The absence of a P/E ratio signals the company remains unprofitable, a common state for biotech firms but one that amplifies execution risk. This combination of elevated short interest, unprofitable operations, and recent underperformance creates potential squeeze dynamics if clinical catalysts emerge, though the elevated short thesis may reflect legitimate concerns about the pipeline's viability or burn rate management.